Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000291619 | SCV000344298 | pathogenic | not provided | 2016-08-22 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000763197 | SCV000893814 | pathogenic | Fabry disease | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000763197 | SCV002054453 | pathogenic | Fabry disease | 2021-07-15 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000763197 | SCV004299649 | pathogenic | Fabry disease | 2022-11-12 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 289868). Disruption of this splice site has been observed in individual(s) with Fabry disease (PMID: 8996967). This variant is not present in population databases (gnomAD no frequency). This sequence change affects an acceptor splice site in intron 1 of the GLA gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in GLA are known to be pathogenic (PMID: 10666480, 12175777). |